immunotherapy

209 projects

HEIndividual fellowship2027–2029France

IT-PREDICT · Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay.

HEIndividual fellowship2027–2029Belgium

LipoTAME · Harnessing engineered lipid nanoparticles to tame autoimmune neuroinflammation by inducing regulatory T cells through CNS myeloid reprogramming

HEIndividual fellowship2027–2028Austria

GlycoIMPACT · Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies

2 partners · 2 countries

HEIndividual fellowship2027–2028United Kingdom

TS-ATM · T cell suppression by antioxidant proteins released into the tumour microenvironment

HEDoctoral network2026–2030Netherlands

ORFeus · Decoding the dark proteome through interdisciplinary training and research

33 partners · 12 countries

HEIndividual fellowship2026–2028Switzerland

ONCAR-TRAIL · TRAIL-armed CAR T cells in combination with ONC206 for diffuse midline gliomas

2 partners

HEIndividual fellowship2026–2029Portugal

NK_LIC2CLUSTER_SR1 · Decoding NK Cell Licensing Through Programmable Nanoscale Clustering and Spatial Mapping

2 partners · 2 countries

HEIndividual fellowship2026–2028Ireland

FluorNano · Fluorinated polymer nanoparticles for mRNA-based cancer therapy

2 partners · 2 countries

HEStaff exchange2026–2029Netherlands

LIGHTHER · First-in-kind anticancer therapy combining light-controllable cytotoxic peptides and dendritic cell-based immunotherapy

6 partners · 3 countries

HEStaff exchange2026–2030Italy

GlioZERO · Advanced technologies for zeroing in on high-grade gliomas

11 partners · 5 countries

HEIndividual fellowship2026–2028Netherlands

T-REaCT · Evolution of T cell reactivity against somatic mutations across human colon cancer stages with single-cell genomics and synthetic T cell specificity screening

3 partners · 2 countries

HEIndividual fellowship2026–2028Luxembourg

LINK-M · Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma

HEIndividual fellowship2026–2028Germany

SIMPL · Spectral Interpretability for Molecular Potentials Learning with Graph Neural Networks

HEIndividual fellowship2026–2028Netherlands

X-CITE · Uncovering the Role of X Chromsome Inactivation Escapees in T Cell Function

HEIndividual fellowship2025–2027Spain

RADIANT-HOPE · Radiomic Analysis and Data Insights for Enhancing Hepatocellular Carcinoma Immunotherapy Outcomes

HEIndividual fellowship2025–2027Sweden

ExpandTILs · Reprogramming cancer cells in dendritic cells to expand tumor-reactive infiltrating lymphocytes.

HEIndividual fellowship2025–2027Portugal

cDcIVA · Nutritional Retinoic Acid as an early cDC2A fate instructive signal in the bone marrow

HEIndividual fellowship2025–2027Italy

RAMPART · Label-Free Raman Approaches for Patient-Specific Biochemical Tumor Mapping to Monitor Personalized Anticancer Resistance Simulation

3 partners · 3 countries

HEIndividual fellowship2025–2028United Kingdom

VASPRINT · Designing Vascular Geometries in 3D Bioprinted Models for Immuno-oncology

2 partners · 2 countries

HEIndividual fellowship2025–2027France

Bio3XBRIT · Unraveling mechanisms of immunotherapy resistance through biomarker profiling in triple-negative breast cancer

HEIndividual fellowship2025–2027Spain

PEPTIM · PEptides Promoting Tolerogenic Interactions with Microbiota

HEIndividual fellowship2025–2027Spain

STRIM-HCC · Defining the role of stromal cells in determining HCC patient response to immunotherapies at single-cell resolution

HEIndividual fellowship2025–2027Germany

TLRT · Enhancing immunotherapies against solid tumors with TLR-switch receptor-armored T cells (TLR-T cells)

HEIndividual fellowship2025–2027Ireland

3DMETACARE · 3D Metastatic Tumor Model Coupled with Targeted mRNA Immunotherapy for the Effective Management of Breast Cancer Brain Metastases